Court Denies Pfizer Request To Halt Sales Of Ivax’ Neurontin Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
A federal judge rejects Pfizer’s motion for a temporary restraining order and preliminary injunction to halt Ivax’ marketing of gabapentin tablets. Court rules that because Ivax’ generic is not AB-rated to Neurontin, Pfizer failed to establish irreparable harm.
You may also be interested in...
Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.
Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.
Pfizer Asks Court To Keep Purepac’s Neurontin Generic Off The Market
Brand company’s arguments in support of a preliminary injunction could be bolstered by the fact that, unlike Ivax’ product, Purepac’s gabapentin generic is AB-rated and the Alpharma division has said a launch would not hinge on resolution of patent litigation with Pfizer.